Grundmann 1987.

Methods	Study design: parallel RCT Study duration: September 1983 to November 1985 Study follow‐up: all followed to November 1986
Participants	Country: Germany Setting: single centre Inclusion criteria: 1st DD kidney transplant recipients Number: treatment group 1 (50); treatment group 2 (50) Mean age ± SD (years): treatment group 1 (38.5 ± 10.8); treatment group 2 (38.7 ± 12.0) Sex ratio (M/F): treatment group 1 (1.9/1); treatment group 2 (1.6/1) Exclusion criteria: not reported
Interventions	Treatment group 1 ALG: 14 days; dose 5 mL/kg/d to max of 30 mL/d via CVC continuous IV infusion PRED: 250 mg day 1, taper by 25 mg/d till 100 mg, then taper by 5 mg/d to 5 to 10 mg/d achieved AZA: max 3 mg/kg/d, depending on WCC platelet count AZA and ALG switched to CSA at day 14 or earlier if unable to tolerate complete ALG course CSA: 8 mg/kg (2 doses), aim for trough levels of 300 ng/mL Treatment group 2 ALG, AZA and steroids: given for 7 days post‐op; thereafter ALG and AZA switched to CSA
Outcomes	Death Graft loss DGF Acute rejection Infection Tolerability of treatment
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not specified if diagnosis of acute rejection was biopsy proven or clinical
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	Unclear risk	Unsure why acute rejection not reported beyond 3 weeks if there were any incidences of any other side effects such as malignancy/PTLD
Other bias	Unclear risk	Funding source not reported